Immunologics, Cancer Drugs Dominate US Medicare’s Third Price Negotiation List

 
• By Cathy Kelly
  
Drug selection kicks off the nine month negotiation process. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Medicare

More from Government Payers